NE NEWS SERVICE
NEW DELHI, JULY 20
A total of 45,432 cases of mucormycosis have been reported by states and UTs till July 15 of which 21,085 affected people are receiving treatment and 4,252 have died, the Rajya Sabha was informed on Tuesday.
A large majority of mucormycosis patients (84.4 percent) had reported a history of COVID-19, Union Health Minister Mansukh Mandaviya said in a written reply.
Most common presentations of mucormycosis include Rhinocerebral (77.6 percent), Cutaneous (4.3 percent) and Pulmonary (3.0 percent).
In the wake of second wave of COVID-19, an increased number of mucormycosis cases were reported and the Ministry of Health after thorough gap analysis and consultations took a number of steps to address the problem.
Mucormycosis and other fungal infections are most commonly seen as an opportunistic infection. They are found in those with low underlying immunity either due to a diabetes, cancers particularly hematological malignancies, etc. or as a side effect of prolonged/irrational use of certain drugs like steroids, immunosuppressive drugs for management of other disorders including COVID-19, the minister explained.
Mandaviya said although it is not a new disease, its true incidence during the beginning of second wave was unknown as it was not a notifiable disease.
The Ministry of Health in May requested states to declare Mucormycosis a notifiable disease under the Epidemic Disease Act to get an objective assessment of the disease.
This extensive speech by Shri @mansukhmandviya covers several aspects relating to COVID-19 in an insightful and sensitive manner. I would request you all to hear his remarks. https://t.co/4uXkE7kQFA
— Narendra Modi (@narendramodi) July 20, 2021
Taking cognizance of association between elevated blood sugar levels (whether in patients with pre-existing diabetes mellitus, or hyperglycemia due to steroid therapy), an updated “Clinical Guidance on Diagnosis and Management of Diabetes at COVID-19 Patient Management facility” was issued by the ministry on June 1.
After expert deliberations in the National Task Force on COVID-19, a detailed advisory on treatment and management of COVID-19 associated Mucormycosis (CAM) was formalized and disseminated on June 7.
Amphotericin-B has been prescribed and it is available in two formulations, Liposomal Amphotericin B and Amphotericin B Deoxycholate, which are similar in efficacy.
However, the latter needs to be used with greater caution with respect to its effects on kidney function test and electrolyte imbalance, the minister explained.
The second drug of choice is Posaconazole which may be used in cases with compromised renal function, drug reaction to Amphotericin B, electrolyte imbalance or in non-availability of Amphotericin B.
A checklist for managing mucormycosis and other fungal infections was also circulated to all states and UTs on June 11.
The clinical management guidelines for managing COVID-19 cases by the ministry advocates rational use of steroids for managing moderate to severe cases of COVID-19 under medical supervision.
For the reporting of cases and deaths due to mucormycosis, the ministry has requested the states and UTs to submit the details on the COVID-19 India portal.
States were asked to update the data on the portal which has helped the ministry to analyse and keep a track of evolving nature of problem.
In response to a question on whether the government has taken cognisance of shortage in supply of Amphotericin-B injections used for the treatment of mucormycosis, Mandaviya said since early May the details of production, stock, supplies made and purchase orders were obtained from manufacturers and their cooperation was sought to overcome the gap between supply and demand.
Both first and second line drugs used for managing mucormycosis cases are currently amply available in Indian markets, he said.
The Department of Pharmaceuticals (DoP), Central Drugs Standard Control Organisation (CDSCO) & National Pharmaceutical Pricing Authority (NPPA) have been jointly monitoring the production and availability of critical Covid drugs including Amphotericin-B injections, he said in the reply.
The Centre has taken various measures to improve the availability of Amphotericin B (liposomal) through a multipronged approach of augmenting production, and import and ensure equitable distribution to states and UTs. It is also engaging with manufacturers to resolve issues related to raw materials.
The Department of Pharmaceuticals and the Indian Embassy in the US are working continuously with Mylan Labs for increasing import and ensuring early delivery from M/s Gilead Inc. USA.
For equitable distribution, allotments are being made to the states and UTs in accordance with the proportion of their reported case load.
Supply arrangements are being monitored by the National Pharmaceuticals Pricing Authority (NPPA) to ensure expeditious availability of the drug, the reply stated.
The NPPA has put in place a strongly responsive system to ensure timely supplies of allocated volumes and maintains continuous contact with states and UTs and suppliers.
The treatment of mucormycosis and other fungal infection is provided free of cost in all Central Government hospitals and autonomous institutions under the ministry, he said in a separate reply.
Ayushman Bharat PM-JAY provides free health cover up to Rs. 5 lakh per year per family. The scheme was launched with 10.74 crore beneficiary families. However, 33 states/UTs have increased the beneficiary base to 13.44 crore families.
Beneficiaries of Ayushman Bharat PM-JAY can avail free treatment of post-COVID related complications, including Mucormycosis, Black Fungus etc. under the scheme.
States are also being supported in terms of allocation and supply of Amphotericin B.
Amphotericin B is being provided at an affordable price under the Pradhan Mantri Bhartiya Janaushadhi Pariyojna (PMBJP).
